Bravis Ziekenhuis | Roosendaal - Cardiology Department
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.
Full description
Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients are either advised to continue letrozole treatment (if Ki67 <1%) or will be randomized between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if Ki67 ≥1%).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion criteria randomization specific:
In order to be eligible to be randomized in this study, a subject must meet all of the following criteria:
Exclusion criteria
Evidence of distant metastases (M1)
Previous invasive breast cancer
Prior chemotherapy, radiation therapy or hormonal therapy with the exception of patients who received letrozole ≤ 14 days (+ max. 4 days) prior to registration and who are still on letrozole.
Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix.
Peripheral neuropathy > grade 2, whatever the cause
Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or QTcF ≥450 msec.
Known hypersensitivity reaction to any of the components of the treatment (peanuts, soy)
Currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.
Currently receiving any of the following substances and cannot be discontinued 7 days prior to randomisation:
Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Primary purpose
Allocation
Interventional model
Masking
100 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal